With a 5-year average revenue growth rate of 23.8%, Insmed Incorporated (NASDAQ:INSM) is included among the The 11 Best Long-Term US Stocks to Buy Right Now.
On May 13, Truist lowered the company’s price target on Insmed Incorporated (NASDAQ:INSM) to $185 from $205, while maintaining a Buy rating on the stock. The analyst said the company updated its model following first-quarter results, taking into account recent competitive developments and adjusting Brinsupri’s estimates based on physician feedback collected after earnings.
During the first quarter 2026 earnings call, Chairman, CEO and President William Lewis said BRINSUPRI, the company’s once-daily oral reversible dipeptidyl peptidase 1 inhibitor (DPPI), achieved sequential growth of 44%. He added that management remained confident in its 2026 revenue outlook of at least $1 billion. Lewis also said the company did not increase the price of BRINSUPRI in early 2026 and noted that the inventory impact during the quarter was minimal.
Analyzing demand trends, Lewis estimated that about 1,500 of the nearly 7,800 new patients who began treatment during the quarter came from the company’s “ready and waiting” patient pool. He added that management believed the momentum tied to those patients had mostly materialized as the company moved into the second quarter. Lewis also noted positive trends in patient access and adherence. It said the approval rate since launch had been close to 90% and noted that more than 80% of patients using BRINSUPRI had joined the company’s inLighten patient support program.
Insmed Incorporated (NASDAQ:INSM) is a global biopharmaceutical company focused on the development of approved and investigational medicines, along with the advancement of drug discovery programs.
While we recognize INSM’s potential as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: The 11 Best Dividend Penny Stocks to Buy Right Now and the 10 Best “Dogs of the Dow” Stocks to Buy for the Rest of 2026
Disclosure: None. Follow Insider Monkey on Google News.